Vaccination with a novel multi-epitope ROP8 DNA vaccine against acute Toxoplasma gondii infection induces strong B and T cell responses in mice

Foroutan, Masoud; Ghaffarifar, Fatemeh; Sharifi, Zohreh; Dalimi, Abdolhossein

doi:10.1016/j.cimid.2020.101413

Cited by 65 publications

(52 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The physicochemical properties predicted in our study were comparable to those predicted by Foroutan et al, in their recently published work [91]. In fact, the instability index and aliphatic index of our vaccine candidate was found to be better when compared to the values reported by [91]. The Ramachandran Plot, ERRAT score, Verify3D score and Z score analysis validated the overall quality of the vaccine construct ( Fig.…”

Section: Discussionsupporting

confidence: 88%

“…They have also performed laboratory validation of their vaccine candidate, which revealed that the multi-epitope vaccine was able to trigger strong humoral and cellular responses in mice [91]. The physicochemical properties predicted in our study were comparable to those predicted by Foroutan et al, in their recently published work [91]. In fact, the instability index and aliphatic index of our vaccine candidate was found to be better when compared to the values reported by [91].…”

Section: Discussionsupporting

confidence: 81%

“…Similarly, Foroutan and his colleagues used the same array of in silico analysis in order to assess the allergenicity and physicochemical properties of their designed vaccine candidate against Toxoplasma gondii [91]. They have also performed laboratory validation of their vaccine candidate, which revealed that the multi-epitope vaccine was able to trigger strong humoral and cellular responses in mice [91]. The physicochemical properties predicted in our study were comparable to those predicted by Foroutan et al, in their recently published work [91].…”

Section: Discussionsupporting

confidence: 78%

“…The half-life of a protein is de ned as the time it takes for the concentration of the protein to be reduced by 50% after its synthesis in the cell. Similarly, Foroutan and his colleagues used the same array of in silico analysis in order to assess the allergenicity and physicochemical properties of their designed vaccine candidate against Toxoplasma gondii [91]. They have also performed laboratory validation of their vaccine candidate, which revealed that the multi-epitope vaccine was able to trigger strong humoral and cellular responses in mice [91].…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

A Candidate Multi-Epitope Vaccine Against Pathogenic Chandipura Vesiculovirus Identified using Immunoinformatics.

Deb

Basak

Kar

et al. 2020

Preprint

View full text Add to dashboard Cite

Chandipura vesiculovirus (CHPV) is a rapidly emerging pathogen responsible for causing acute encephalitis. Due to its widespread occurrence in Asian and African countries, this has become a global threat, and there is an urgent need to design an effective and non-allergenic vaccine against this pathogen. The conventional method of vaccine design involves large proteins or whole organism which leads to unnecessary antigenic load with increased chances of allergenic reactions. In addition, the process is also very time consuming and labour intensive. These limitations can be overcome by peptide-based vaccines comprising of short immunogenic peptide fragments that can elicit highly targeted immune responses, avoiding the chances of allergenic reactions, in a relatively shorter time span. The multi-epitope vaccine constructed using CTL, HTL and IFN-γ epitopes was able to elicit specific immune responses when exposed to the pathogen, in-silico. Not only that, Molecular Docking and Molecular Dynamics Simulation studies confirmed a stable interaction of the vaccine with the immune receptors. Several physicochemical analyses of the designed vaccine candidate confirmed it to be highly immunogenic and non-allergic. The computer-aided analysis performed in this study suggests that the designed multi-epitope vaccine can elicit specific immune responses and can be a potential candidate against CHPV.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionsupporting

confidence: 81%

Section: Discussionsupporting

confidence: 78%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

A Candidate Multi-Epitope Vaccine Against Pathogenic Chandipura Vesiculovirus Identified using Immunoinformatics.

Deb

Basak

Kar

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The half-life of the vaccine was evaluated to be 30 h (mammalian reticulocytes, in vitro), > 20 h (yeast, in vivo) and > 10 h (Escherichia coli, in vivo) which indicates the time taken by the protein to reach 50% of its concentration after its synthesis in the cell. Similarly, Foroutan and his colleagues have also used the same array of in silico analysis in order to assess the allergenecity and physicochemical properties of their designed vaccine candidate against Toxoplasma gondii 92 . They have also performed laboratory validation of their vaccine candidate, which revealed that the multi-epitope vaccine was able to trigger strong humoral and cellular responses in mice 92 .…”

Section: Discussionmentioning

confidence: 99%

A candidate multi-epitope vaccine against SARS-CoV-2

Kar¹,

Narsaria²,

Basak³

et al. 2020

Sci Rep

268

172

View full text Add to dashboard Cite

In the past two decades, 7 coronaviruses have infected the human population, with two major outbreaks caused by SARS-CoV and MERS-CoV in the year 2002 and 2012, respectively. Currently, the entire world is facing a pandemic of another coronavirus, SARS-CoV-2, with a high fatality rate. The spike glycoprotein of SARS-CoV-2 mediates entry of virus into the host cell and is one of the most important antigenic determinants, making it a potential candidate for a vaccine. In this study, we have computationally designed a multi-epitope vaccine using spike glycoprotein of SARS-CoV-2. The overall quality of the candidate vaccine was validated in silico and Molecular Dynamics Simulation confirmed the stability of the designed vaccine. Docking studies revealed stable interactions of the vaccine with Toll-Like Receptors and MHC Receptors. The in silico cloning and codon optimization supported the proficient expression of the designed vaccine in E. coli expression system. The efficiency of the candidate vaccine to trigger an effective immune response was assessed by an in silico immune simulation. The computational analyses suggest that the designed multi-epitope vaccine is structurally stable which can induce specific immune responses and thus, can be a potential vaccine candidate against SARS-CoV-2. Wuhan, a city in China, witnessed the outbreak of a febrile respiratory illness on 19th December 2019 due to the coronavirus provisionally named as 2019-nCoV and later SARS-CoV-2 1,2. The disease caused by this coronavirus was named as COVID-19 1,2. Since then, the world is experiencing a grave situation of global public health emergency due to the viral pandemic of severe febrile pneumonia like respiratory syndrome caused by the novel coronavirus 2. Coronaviruses are known to have caused three epidemics in the last two decades, namely COVID-19 in 2019/20, Severe Acute Respiratory Syndrome (SARS) in 2002, and Middle East Respiratory Syndrome (MERS) in 2012 3. As of June 3rd 2020, total cases of SARS-CoV-2 confirmed globally by World Health Organization are 6,287,771 with 379,941 reported deaths (https ://www.who.int/emerg encie s/disea ses/ novel-coron aviru s-2019/situa tion-repor ts). Human coronavirus (H-CoV) is a member of Coronaviridae family, a virus family characterized with the largest RNA genome (26-32 kb), among all of the viruses known till date 4-6. A lipid envelope bilayer containing the spike and membrane proteins surround the positive stranded RNA genome of this virus 7. The spike protein binds to the host cell receptors and releases the viral genome into the host cell, thereby facilitating the viral replication 8. Coronaviruses (CoVs) are mostly associated with respiratory illness and common cold 9 , but can also cause infections in Central Nervous System (CNS) 10. To date, four genera of coronaviruses (α, β, γ, δ) have been identified 11. Human coronaviruses (H-CoVs) belong to α (HCoV-229E and NL63) and β (MERS-CoV, SARS-CoV, HCoV-OC43, HCoV-HKU1 and SARS-CoV-2) genera of coronavirus, respectively 11. In late De...

show abstract

Immunoinformatics based designing a multi‐epitope vaccine against pathogenic Chandipura vesiculovirus

Deb

Basak

Kar

et al. 2021

J of Cellular Biochemistry

View full text Add to dashboard Cite

Chandipura vesiculovirus (CHPV) is a rapidly emerging pathogen responsible for causing acute encephalitis. Due to its widespread occurrence in Asian and African countries, this has become a global threat, and there is an urgent need to design an effective and nonallergenic vaccine against this pathogen. The present study aimed to develop a multi‐epitope vaccine using an immunoinformatics approach. The conventional method of vaccine design involves large proteins or whole organism which leads to unnecessary antigenic load with increased chances of allergenic reactions. In addition, the process is also very time‐consuming and labor‐intensive. These limitations can be overcome by peptide‐based vaccines comprising short immunogenic peptide fragments that can elicit highly targeted immune responses, avoiding the chances of allergenic reactions, in a relatively shorter time span. The multi‐epitope vaccine constructed using CTL, HTL, and IFN‐γ epitopes was able to elicit specific immune responses when exposed to the pathogen, in silico. Not only that, molecular docking and molecular dynamics simulation studies confirmed a stable interaction of the vaccine with the immune receptors. Several physicochemical analyses of the designed vaccine candidate confirmed it to be highly immunogenic and nonallergic. The computer‐aided analysis performed in this study suggests that the designed multi‐epitope vaccine can elicit specific immune responses and can be a potential candidate against CHPV.

show abstract

Vaccination with a novel multi-epitope ROP8 DNA vaccine against acute Toxoplasma gondii infection induces strong B and T cell responses in mice

Cited by 65 publications

References 57 publications

A Candidate Multi-Epitope Vaccine Against Pathogenic Chandipura Vesiculovirus Identified using Immunoinformatics.

A Candidate Multi-Epitope Vaccine Against Pathogenic Chandipura Vesiculovirus Identified using Immunoinformatics.

A candidate multi-epitope vaccine against SARS-CoV-2

Immunoinformatics based designing a multi‐epitope vaccine against pathogenic Chandipura vesiculovirus

Contact Info

Product

Resources

About